As Rakuten Medical’s President Minami Maeda puts it: “Innovation isn’t just great science; if it doesn’t get implemented to save patients, it’s not innovation.”.
Rakuten Medical’s Alluminox™ platform represents a shift in molecularly targeted therapy, utilizing a drug-device system known as photoimmunotherapy. The journey of Alluminox™ reached a critical peak this year at the 2025 Innovation Awards in Taiwan, where the platform was recognized for its potential to transform oncology. The accolade serves as more than just a trophy; it is a validation of Rakuten’s “execution-first” philosophy. For Maeda, the award underscores the synergy between advanced Taiwanese medical infrastructure and Rakuten’s light-based technology.
1views
